Subcutaneous REGEN-COV antibody administration in a community pharmacy.
J Am Pharm Assoc (2003)
; 63(3): 961-966, 2023.
Article
in English
| MEDLINE | ID: covidwho-2229580
ABSTRACT
BACKGROUND:
REGEN-COV is a non-Food and Drug Adminstration approved monoclonal antibody combination of casirivimab/imdevimab. Casirivimab/imdevimab was previously used for the treatment of SARS-CoV-2 infection (COVID-19), under an emergency use authorization, and has demonstrated a reduction in hospitalizations and death. With the ability to administer this monoclonal antibody combination subcutaneously in an outpatient setting, limited community pharmacies became a treatment location for patients.OBJECTIVES:
The objective of this study was to describe an innovative service and evaluate the safety of administering REGEN-COV, a monoclonal antibody combination of casirivimab and imdevimab, in a community pharmacy setting as treatment for COVID-19. PRACTICE DESCRIPTION This study was conducted in a community pharmacy during traditional business hours. PRACTICE INNOVATION A novel service of monoclonal antibody administration for the treatment of COVID-19 was implemented in a community pharmacy in response to community needs during the pandemic. EVALUATIONMETHODS:
A retrospective, observational study was conducted from September 1, 2021 to December 31, 2021. Patients were required to have a positive SARS-CoV-2 test and meet all inclusion and exclusion criteria. Patients were assessed for adverse drug reactions at the time of monoclonal antibody administration and 60-minutes after administration. Patients were contacted by phone to complete a survey to assess patient reported adverse drug reactions post administration, number of patients hospitalized, and number of patients able to return to normal daily activities.RESULTS:
Of the 93 patients included in this study, adverse effects were reported in 4.3% of patients at administration and 9.7% at follow-up. Included patients receiving this service generated $32,688.68 in revenue for the community pharmacy.CONCLUSION:
Community pharmacists can administer casirivimab/imdevimab safely and effectively in an outpatient setting with low adverse events. This innovative monoclonal antibody administration service should be used as an example for a Call to Action of expansion of pharmacist scope of practice.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pharmacies
/
Drug-Related Side Effects and Adverse Reactions
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Am Pharm Assoc (2003)
Journal subject:
Pharmacy
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS